COMPUMEDICS LIMITED — Investor Presentation 2015

Oct 28, 2015

==> picture [720 x 5] intentionally omitted <==

Compumedics Limited Corporate Presentation – September 2015

1

AGM - Agenda

==> picture [720 x 5] intentionally omitted <==

• Meeting Opens

• Chairman's Address

• Ordinary Business

• Meeting Closes

2

Investor Overview

==> picture [720 x 5] intentionally omitted <==

• :

• FY 15 Highlights $33.5m sales, revenue growth 9%, EBITDA $4.1m, NPAT $2.0m

• Core business: now highly profitable and continues to grow with the full benefits of the earnings initiatives undertaken in recent years still to flow through.

• New Product platform roll out to significantly expand our addressable market

• Growth in international sales with expansion plans in the US, Germany and China

• eHealth: Pushing ahead with the commercialization of our cloud based sleep diagnostics platform

• DWL expansion opportunity with newly granted breakthrough auto-scan TCD patent and Neuroscan foray into much larger brain analysis imaging market

• Spin offs/strategic decisions to unlock significant value for shareholders continue to be pursued

• FY16 guidance: Sales $36m-$38m, EBITDA $4.5m-$5.5m, NPAT $2.8m-$3.2m.

(1) RFM:15215; (2) RFM: 15218; (3) RFM: 15214

Who is Compumedics?

==> picture [720 x 5] intentionally omitted <==

• Compumedics is a leading global, innovative developer and manufacturer of medical devices for:

• Diagnosing sleep disorders

• Monitoring neurological disorders including long-term epilepsy monitoring (LTEM)

• Highly sophisticated brain research

• Ultrasonic monitoring of blood flow through the brain (Transcranial Doppler [TCD])

• Compumedics is a technological leader in its chosen markets:

• 1 Australia sleep & neuro diagnostics device supplier

• 1Japan sleep diagnostics device supplier

• 1 China sleep diagnostic device supplier to China’s premier facilities & #1 TCD device supplier

• 3 USA sleep diagnostic device supplier and emerging #3 supplier for neurological monitoring devices

• Compumedics has a rich intellectual property portfolio

• Compumedics e-Health platform is the next growth phase in the company’s development

• Compumedics listed ASX Dec 21, 2000

4

Directors & Executive Team Key Management

==> picture [720 x 5] intentionally omitted <==

==> picture [68 x 59] intentionally omitted <==

==> picture [319 x 161] intentionally omitted <==

----- Start of picture text -----

David Burton, Ph.D.
Executive Chairman, CEO
Founder, Tenure 26yrs
NED Mr. David Lawson
Mr. Alan Anderson Chief Financial Officer &
Leading USA Attorney Company Secretary
CMP Tenure : 11 yrs CMP Tenure 13 yrs
----- End of picture text -----

==> picture [85 x 75] intentionally omitted <==

==> picture [560 x 114] intentionally omitted <==

----- Start of picture text -----

Mr. Warwick Freeman Kerry Hubick, Ph.D . Mr. Christoph Witte
Chief Technology Officer Trademark, Patent & General Managing Director Compumedics Germany
CMP Tenure 15 yrs General Legal Attorney GmbH CMP/DWL
Tenure 24 yrs
CMP Tenure 7 yrs
----- End of picture text -----

5

A Tradition of Innovation

==> picture [720 x 5] intentionally omitted <==

==> picture [720 x 388] intentionally omitted <==

----- Start of picture text -----

Comperio DQ Summit IP
SynAmps2 2004 2005
Somté 2003
2001 Siesta 802
Siesta
2005
2000
P Series
1994
S Series
1987
Somté PSG
2006
Neuvo LTM
SynAmpsRT 2007
2008
CURRY6
Somnilink SPAP 2009
2010
Grael HD
Somfit
2010
2015 Somté PSG 2.0
2011
----- End of picture text -----

6

Established Client Profile

==> picture [720 x 5] intentionally omitted <==

==> picture [138 x 74] intentionally omitted <==

==> picture [68 x 84] intentionally omitted <==

==> picture [71 x 71] intentionally omitted <==

==> picture [153 x 47] intentionally omitted <==

==> picture [168 x 17] intentionally omitted <==

==> picture [54 x 55] intentionally omitted <==

==> picture [50 x 30] intentionally omitted <==

==> picture [50 x 12] intentionally omitted <==

==> picture [114 x 39] intentionally omitted <==

==> picture [144 x 21] intentionally omitted <==

==> picture [45 x 45] intentionally omitted <==

==> picture [90 x 25] intentionally omitted <==

==> picture [37 x 42] intentionally omitted <==

==> picture [140 x 20] intentionally omitted <==

==> picture [174 x 67] intentionally omitted <==

==> picture [49 x 45] intentionally omitted <==

==> picture [106 x 30] intentionally omitted <==

==> picture [192 x 52] intentionally omitted <==

==> picture [162 x 17] intentionally omitted <==

==> picture [128 x 34] intentionally omitted <==

==> picture [108 x 39] intentionally omitted <==

==> picture [126 x 32] intentionally omitted <==

==> picture [126 x 50] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

7

==> picture [720 x 5] intentionally omitted <==

Core Sleep and Brain Diagnostic Monitoring Business

==> picture [720 x 192] intentionally omitted <==

8

FY15 Results

==> picture [720 x 5] intentionally omitted <==

• Revenue and profit figures in line with guidance

• New sales orders taken in FY2015 were 19% higher than new sales orders taken in FY2014. Driven by growth in US, China and Europe.

• Sales order backlog continues to decline, although late rush of sales orders received at 30 June 2015 does not make that apparent with $5.5m of sales orders on hand at 30 June 2015 compared to $6.0m at same time last year.

9

Revenue Composition at ≈$33m 30 June 2015

==> picture [720 x 5] intentionally omitted <==

By geographic region

By product/market

==> picture [267 x 260] intentionally omitted <==

----- Start of picture text -----

Europe,
16% USA,
34%
Asia,
34%
Aust,
16%
----- End of picture text -----

==> picture [315 x 270] intentionally omitted <==

----- Start of picture text -----

Tech.
Supply
Service,
Items, 8% Sleep,
9%
28%
Brain
Neuro,
Blood
12%
Flow, Brain
21% Res,
21%
----- End of picture text -----

Software upgrades 5 to 10% of system sales

Compumedics sells directly to end-user customers in Australia, USA and Germany and through its network of more than 50 distributors to all other parts of the world

10

Core Business Overview

==> picture [720 x 5] intentionally omitted <==

• The core business has returned to strong operating profitability and is positioned for significant earnings growth in the years ahead

• Cost reduction initiatives for the assembly and manufacture of key products are yet to fully flow through to the bottom line, expected to occur in FY16

• With both redesigned and new products released to market we will be in a position to aggressively expand sales, particularly in the US market

• ®

• Compumedics technology is world leading. We now have a competitive cost base to bring that leading technology to the mass market (vs previously the premium market)

• 20,000 installed systems worldwide. Strong brand name and reputation. Customers like buying Compumedics.

11

International Growth – Geographic Expansion

==> picture [720 x 5] intentionally omitted <==

• Expand our US sales force and management team to further build our market presence in the largest markets for sleep diagnostics and neurology.

• Establish an office in Germany, a relatively untapped market for Compumedics to date.

• Push into the Chinese neurology market – a massive, untapped and rapidly growing opportunity. We are already no.1 in premium sleep diagnostics with extensive long term relationships with major distributors.

12

Product Matrix

==> picture [720 x 5] intentionally omitted <==

Product		Used for	Bought by	Average selling price
Grael		Sleep and neurology	Hospitals, doctors and service providers	USD17,500
Somte PSG		Sleep	Hospitals, doctors and service providers	USD10,000
Siesta		Sleep and neurology	Hospitals, doctors and service providers	USD18,000
Neuvo LTM		Neurology	Hospitals, doctors and service providers	USD35,000
Synamps RT		Brain Research	Universities and teaching hospitals	USD38,000
CURRY		Brain research and neurology	Universities, teaching hospitals and regular hospitals	USD20,000

13

Historical Full Year Revenues

12 months to 30 June

==> picture [720 x 5] intentionally omitted <==

0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0	Shipped and invoiced
	FY2013 FY2014 FY2015 F'cast FY2016 H1 Rev F'Cast Rev

==> picture [720 x 35] intentionally omitted <==

Historical Full Year Earnings

12 months to 30 June

==> picture [720 x 5] intentionally omitted <==

NPAT

EBITDA

==> picture [671 x 269] intentionally omitted <==

----- Start of picture text -----

3.5 6
3
5
2.5
2
4
1.5
3
1
0.5
2
0
-0.5 FY2013 FY2014 FY2015 Fcast 1
FY2016
-1
0
-1.5
FY2013 FY2014 FY2015 Fcast
-2 FY2016
----- End of picture text -----

==> picture [10 x 11] intentionally omitted <==

NPAT F'Cast NPAT EBITDA F'Cast EBITDA

Full year EBITDA for FY2016 is estimated between $4.5m and $5.5m. Excluding Medical Innovation costs EBITDA is estimated between $5.5m to $6.5m

==> picture [720 x 35] intentionally omitted <==

Employee Composition at ≈120 staff 30 June 2015

==> picture [720 x 5] intentionally omitted <==

By geographic region

By function

==> picture [302 x 246] intentionally omitted <==

----- Start of picture text -----

Mid
Asia,
East,
3%
1% USA &
LA,
31%
Europe,
30%
Aust,
35%
----- End of picture text -----

==> picture [316 x 240] intentionally omitted <==

----- Start of picture text -----

Admin
Sales &
Quality,
& Fin,
Mark,
2%
Manuf, 14%
23%
20%
Service,
R&D, 19%
22%
----- End of picture text -----

Compumedics has its Head Office in Melbourne, Australia with additional offices in Charlotte (NC), USA and Singen, Germany

16

Tide turning post GFC and high AUD

==> picture [720 x 5] intentionally omitted <==

==> picture [634 x 370] intentionally omitted <==

----- Start of picture text -----

45,000 5,000
40,000
4,000
35,000
3,000
30,000
25,000 2,000
20,000 1,000
15,000
-
10,000
-1,000
5,000
- -2,000
2009 2010 2011 2012 2013 2014 2015
Revenues EBITDA
1.2000
1.0000
0.8000
0.6000
0.4000
0.2000
0.0000
2009 2010 2011 2012 2013 2014 2015
AUD/USD Exchange rate
----- End of picture text -----

17

Growth Drivers – Core business

==> picture [720 x 5] intentionally omitted <==

• Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology

• We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics.

• Earnings initiatives to flow through in FY16.

• Opportunity to significantly grow the USA business through strengthening of the management team and expansion of the sales force.

• Expansion into untapped German market

• Push into the Chinese neurology market

• Ideally positioned to accelerate organic growth and value realisation

18

Earnings improvement activities

==> picture [720 x 5] intentionally omitted <==

• Outsourcing Manufacturing – lower cost regions of China and Taiwan

• EEG cap production completely relocated at Dec 14 and Grael production to be completed by Dec 2015

• Offshore or specialist purchasing houses to increase quality and drive down costs. Grael and Somte purchasing relocation complete Dec 2015

• Streamlining of logistics (final product assembly, testing and shipment) as the business grows

• Completed redesign of all major product lines for aggressive global full market access - based on at least halving cost of goods but retaining quality and performance

• New generation Grael to be released for sale Dec 2015

• These benefits will start to flow through in FY16 and beyond

19

Growth Strategies – core business USA Clinical Sales Force Expansion

==> picture [720 x 5] intentionally omitted <==

More sales representatives > more revenue for both sleep and neurology

Past

==> picture [403 x 58] intentionally omitted <==

USD4.5m

FY2015 - Now

==> picture [194 x 58] intentionally omitted <==

USD6.4m

FY2016

==> picture [267 x 58] intentionally omitted <==

USD10.0m

FY2017

==> picture [330 x 57] intentionally omitted <==

USD15.0m

==> picture [720 x 35] intentionally omitted <==

China - We are the number 1 Premier Supplier

Compumedics Clients in China

==> picture [720 x 411] intentionally omitted <==

----- Start of picture text -----

China Sales – USD’s
10
5
0
FY12 FY13 FY14 FY15
----- End of picture text -----

21

==> picture [720 x 5] intentionally omitted <==

Strategic Value Realisation

==> picture [720 x 193] intentionally omitted <==

22

Strategic value realisation

==> picture [720 x 5] intentionally omitted <==

The company is currently considering options to simplify its business and unlock significant value for shareholders by:

• Spinning out its Germany based DWL Transcranial Doppler (TCD) ultrasound blood flow business

• Spinning out its Brain Research business (NeuroScan)

23

DWL Spin out opportunity

==> picture [720 x 5] intentionally omitted <==

• DWL is the founding business and global leader in TCD ultrasound.

• Short term growth opportunities in 3D Transcranial Colour Doppler (TCCD)/Duplex Imaging

• Medium term growth opportunities in TBI and Stroke Market

• 3D TCCD is a US$900m vs DWL’s current market of $US30m. Relatively small investment required in upgrading the user interface to be able to play in this market.

• Traumatic Brain Injury (TBI) – DWL work with some of the world’s most respected researchers.

• Continue to build commercial momentum with 3D TCCD and TBI opportunities, with a view to spinning these out as circumstances and timing allow.

• Substantial potential DWL value realisation based on revenue multiples of comparable entities:

• Revenue of $US6m (based on 4x current revenue) = $US24m

• Compumedics remains focused on continued DWL business growth in

• conjunction with the acceleration of organic growth and value realisation

24

Brain Research Spin Out Opportunity

==> picture [720 x 5] intentionally omitted <==

• Growth outlook – significant for Neuroscan CURRY – World’s best of class brain analysis software

• Enormous neurology devices demand – est. $7bn pa by 2017 up from $2bn in 2010

• CURRY multi modal brain analysis technology – traditional research market - $50m pa

• CURRY – multi modal brain analysis monitoring – new imaging market - $4bn pa

• CURRY – MEG Imaging – currently the preferred solution

• NeuroScan/CMP – 9% revenue growth expected. EBITDA approx. $1.1m

• Similar AIM IPO comparable – post money 5x revenue market capitalization

• Compumedics remains focused on continued Neuroscan business growth in conjunction with the acceleration of organic growth and value realisation

25

==> picture [720 x 5] intentionally omitted <==

eHealth – Next Phase in Compumedics Growth

==> picture [720 x 193] intentionally omitted <==

26

Medical Innovations – eHealth

==> picture [720 x 5] intentionally omitted <==

• Compumedics is developing eHealthMedics, an online professional sleep services platform

• Sleep diagnostics is traditionally delivered as a lab-based (equipment intense) or Home Sleep Testing service eHealthMedics has re-architected its solution such that the sleep monitoring and algorithms that translate the raw data into sleep stages run on the cloud, so that all that is required on-site is a mobile sleep system to buffer and transfer the raw data

• The platform is based on Compumedics’ core world-class sleep diagnostic technology, built up over more than two decades and $100m+ in accumulated R&D and $500m+ in total system sales

• eHealthMedics will provide the backbone and infrastructure to professional sleep service providers

27

==> picture [332 x 49] intentionally omitted <==

eHealthMEDICS - Competitive Advantage

==> picture [720 x 5] intentionally omitted <==

• The scalability and cost efficiencies of eHealthMedics vs traditional sleep diagnostics allow the service to accommodate very large sleep-disordered populations, even in regions where private or public health insurance is limited or non-existent (eg China – a key market for eHealthMedics)

• The numerous validated and proven algorithms & report templates have been developed over 25+ years of ongoing R&D – they cannot be replicated

• Compumedics possess a broad spectrum of medical diagnostic and monitoring technologies that are unrivalled globally

• These technologies have served clients including NASA, Stanford, Mayo Clinic, Yale, Beijing University, University of Tokyo and a range of leading hospitals worldwide, as well as provided the infrastructure for the worlds largest home based sleep study and database of its kind – the USA National Institute of Health’s ‘Sleep Heart Health Study’

• The above provides eHealthMedics with the ability to leverage existent proven systems and relationships into the professional sleep services space with “gold standard”, regulatory approved and certified diagnostic technology backed by key opinion leaders within the industry

==> picture [720 x 35] intentionally omitted <==

eHealthMEDICS – Making Progress

==> picture [720 x 4] intentionally omitted <==

• eHealthMedics has already locked in excess of $10m of forward orders over the next three years (primarily in China) for its professional services platform. Initial pilot sites commence in May and June this year

• Operational systems have been developed for the cloud based capture, transfer and translation of medical grade sleep parameters from any web-enabled device. The system can then store, analyse

• and interpret that data in a simple and actionable manner, reducing the need for on-site professionals

• Compumedics are now approaching a select group of strategic partners/investors to expedite the process and rapidly deploy the platform to market

• Key partners being pursued include web, telco, eHealth, consumer health/electronics providers and device manufacturers

• Compumedics will update the market as significant further progress is achieved

==> picture [720 x 35] intentionally omitted <==

eHealthMEDICS - We bring to the table a eHealth services platform that leverages core competencies built over 25 years

==> picture [720 x 5] intentionally omitted <==

mHealth Product Ecosystem: Required Competencies [traditional business]

==> picture [689 x 333] intentionally omitted <==

----- Start of picture text -----

• Inc. medical data security
[traditional business]
(FDA, CE, TGA compliant, US
est. 1987
HIPPS)
• Medical grade • Established
Cloud
‘life-signals’
global
Over 250 product patents monitoring Medical Regulatory
network of
Established medical Data Compliance Physicians
credentials - 000s of medical Processing
publications / leading R&D Patents / Health
team IP Services
Government / regulatory
certification and compliance
new
Clinical diagnostic software Clinical
(inc. sleep disorders, neurology, Govt. mHealth
Grade
heart, epilepsy, diabetes) Funding Platform
Products
Medical monitoring devices –
home and hospital
Cloud-based algorithms, data • Eligibility for •
Applications
processing and security govt. health • Network
scheme rebates
----- End of picture text -----

• Over 250 product patents

• Established medical

• credentials - 000s of medical publications / leading R&D team

• Government / regulatory certification and compliance

• Clinical diagnostic software (inc. sleep disorders, neurology, heart, epilepsy, diabetes)

• Medical monitoring devices – home and hospital

• Cloud-based algorithms, data processing and security

• Global Network of Physicians

• Sensors / wearables

• Clinical monitoring sensors

==> picture [103 x 35] intentionally omitted <==

==> picture [41 x 20] intentionally omitted <==

==> picture [720 x 35] intentionally omitted <==

Investor Summary

==> picture [720 x 5] intentionally omitted <==

• Core business continues to grow

• International sales force expansion, neurology market opportunity and earnings improvement initiatives to continue to drive growth of core business

• Compumedics remains committed to continuing to deliver superior returns to shareholders

• e-Health platform is the next step for CMP’s growth. Moving 25+years and $100m+ in cumulative R&D to a modern platform to solve a massive and growing problem. $10m of contracts already locked in.

• Spin off/strategic decisions to unlock significant value, provide funds for growth and potentially capital returns to shareholders

• FY16 guidance: Sales $36m-38m, $4.5m-$5.5m EBITDA, NPAT $2.8m$3.2m

31

Ordinary Business

• Item 1 Financial Statements and Reports

• Item 2 Re-election of Director – David Lawson

• Item 3 Adoption of Remuneration Report (non-binding resolution)

32

Meeting Closes

Refreshments are available in the main reception area, where additional questions and discussion are encouraged, for those who are interested.

33

==> picture [720 x 5] intentionally omitted <==

34